Key Highlights

  • Shares fell 18.38% to USD 0.0955 in pre-market trading on November 4, 2026.
  • First half 2026 Revenue climbed 24.6% to USD 9.92 million, with gross Margin at 87.0%.
  • Cash and restricted cash was USD 289,083 at June 30, 2026.
  • A China distribution agreement covering 19 markets was announced on November 2, 2026.
  • The distributor placed an initial order of about RMB 6 million, roughly USD 900,000.

What Moved Baird Medical Before the Open (down USD 0.0215, 18.38%)

Baird Medical Investment Holdings (NASDAQ:BDMD) fell 18.38% to USD 0.0955 in pre-market trading on November 4, 2026, a drop of USD 0.0215 from an implied Tuesday close of about USD 0.1170 (calculated). The shares have been volatile since a company press release dated November 2, 2026.

No company announcement dated November 3 or November 4, 2026 was found that explains the decline. With a share price under USD 0.12 and limited cash, the move may reflect continued selling in a very low priced stock, which is an inference and not a confirmed cause.

The China Distribution Agreement

According to the November 2, 2026 press release, the company's China subsidiary, Nanjing Changcheng Medical Equipment Company Limited, signed an agreement with a medical devices unit of a Hong Kong listed pharmaceutical group. The distributor becomes the exclusive channel for specified microwave ablation products in 19 key China markets, aimed at regions where Baird Medical has had limited direct presence.

On signing, the distributor placed an initial order of about RMB 6 million, roughly USD 900,000 according to the company. Chairwoman and Chief Executive Officer Haimei Wu said the Partnership should speed up access to hospitals in previously untapped regions.

Business Background and Recent Results

Baird Medical is a medical device company focused on minimally invasive ablation for solid tumors. Its microwave ablation system is FDA cleared for soft tissue ablation and is being launched in the United States mainly for benign thyroid nodules. It is also developing irreversible electroporation technology and an AI powered robotic ablation system.

In a press release dated September 3, 2026, the company reported unaudited results for the six months ended June 30, 2026. Revenue rose 24.6% to USD 9.92 million from USD 7.96 million, Gross Profit rose 32.0% to USD 8.62 million, and gross margin reached 87.0% from 82.1%. Operating expenses fell about 54% to USD 7.78 million, and the company reported Net Income of USD 13,499, against a net loss of USD 11.36 million a year earlier.

Balance Sheet and Risks

Cash and restricted cash was USD 289,083 on June 30, 2026, down from USD 565,817 at December 31, 2025. Total liabilities were USD 39.22 million against total Assets of USD 73.85 million, and the short term Loan balance was USD 10.76 million. The company provided no financial guidance.

At USD 0.0955 per share this is a penny stock, where thin liquidity, wide spreads and dilution risk can amplify price swings in either direction. An initial order of about USD 900,000 is a starting point, and the exclusive arrangement does not by itself set the pace of future orders.

What to Watch Next

Key items include any disclosure of follow on orders under the distribution agreement, progress on the United States thyroid nodule launch, and filings that address financing or Nasdaq listing requirements. Given the thin cash balance at June 30, 2026, the funding path is likely to draw close attention.